N-Benzylpyrrolidine Compounds with MAO-B Inhibitory Activity in an Experimental Model of Parkinson’s Disease
International Journal of Molecular Sciences · 09.03.2026 · 27 (5) · 2496
DOI: 10.3390/ijms27052496 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.03.2026. Verfasst von Jane Tchekalarova und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neurobiology, Bulgarian Academy of Sciences, 1000 Sofia, Bulgaria. Hauptthemen laut MEDLINE: Pyrrolidines, Monoamine Oxidase Inhibitors, Monoamine Oxidase, Parkinson Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "Strategic Research and Development Innovation Program of Medical University-Sofia", Strategic Research and Development Innovation Program of Medical University-Sofia.
Abstract (Originalsprache)
The pathogenesis of Parkinson’s disease (PD) is characterized by progressive degeneration of nigrostriatal dopaminergic signaling, resulting in motor dysfunction. Although monoamine oxidase (MAO) inhibitors are clinically used in PD, their long-term efficacy and safety remain limited. In the present study, three novel N-benzylpyrrolidine derivatives (3e, 3f, and 3i), previously identified as dual MAO-A/B inhibitors in silico and in vitro, were pharmacologically evaluated in an acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. The compounds were administered intraperitoneally starting 2 days prior to MPTP exposure and continuing for 6 days thereafter. Repeated administration of the compounds did not alter striatal dopamine (DA) levels under basal conditions, indicating no detectable modulation of dopaminergic tone in vivo. All three derivatives ameliorated MPTP-induced motor deficits. Compounds 3f and 3i improved motor function without detectable changes in striatal DA levels, whereas compound 3e partially restored striatal DA levels, similar to the positive control. In addition, compound-specific alterations in hippocampal pro-inflammatory cytokines were observed, including increased levels of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) following 3e administration. Together, these findings provide in vivo pharmacological characterization of novel MAO-targeting derivatives and reveal differential behavioral, neurochemical, and cytokine profiles among the tested compounds, supporting further mechanistic investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Neurobiology, Bulgarian Academy of Sciences, 1000 Sofia, Bulgaria.
- Department of Chemistry, Faculty of Pharmacy, Medical University-Sofia, 1431 Sofia, Bulgaria.
ORCID-Profile: Jane Tchekalarova
Förderung
- "Strategic Research and Development Innovation Program of Medical University-Sofia"
- Strategic Research and Development Innovation Program of Medical University-Sofia
Zitieren
APA
Tchekalarova, J., Ivanova, P., Angelova, V. T., Bogdanova, N., Bozhanov, S., Smerikarova, M., & Maslarska, V. (2026). N-Benzylpyrrolidine Compounds with MAO-B Inhibitory Activity in an Experimental Model of Parkinson’s Disease. International Journal of Molecular Sciences, 27(5), 2496. https://doi.org/10.3390/ijms27052496
Vancouver
Tchekalarova J, Ivanova P, Angelova VT, Bogdanova N, Bozhanov S, Smerikarova M, et al. N-Benzylpyrrolidine Compounds with MAO-B Inhibitory Activity in an Experimental Model of Parkinson’s Disease. International Journal of Molecular Sciences. 2026;27(5):2496. doi:10.3390/ijms27052496
BibTeX
@article{Tchekalarova2026,
author = {Tchekalarova, Jane and Ivanova, Petj and Angelova, Violina T and Bogdanova, Nicol and Bozhanov, Stanislav and Smerikarova, Miglena and Maslarska, Vania},
title = {N-Benzylpyrrolidine Compounds with MAO-B Inhibitory Activity in an Experimental Model of Parkinson’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {5},
pages = {2496},
doi = {10.3390/ijms27052496}
}
EUVIMED